AIBT / Aibotics Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Aibotics, Inc. (Exact

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): oForm 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 2025 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Period

AIBOTICS, INC. formerly Mycotopia Therapies Inc. 100 SE 2nd St Suite 2000 Miami, FL 33131 Phone: (954) 903-7856 Maximum Offering: $5,000,000 of Common Stock Minimum Purchase per Investor: $5,000 Up to a Maximum of 5,000,000,000 Common Shares $.003 pe

SEC FORM Filed pursuant to Rule 253(g)(2) File No. 024-12597 AIBOTICS, INC. formerly Mycotopia Therapies Inc. 100 SE 2nd St Suite 2000 Miami, FL 33131 Phone: (954) 903-7856 Maximum Offering: $5,000,000 of Common Stock Minimum Purchase per Investor: $5,000 Up to a Maximum of 5,000,000,000 Common Shares $.003 per Share This is the public offering of securities of Aibotics, Inc., a Nevada corporation

CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

Microsoft Word - {87C530D3-C967-4C0F-978A-8A76D3ADB243} CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in this Registration Statement to Form 1-A, Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 4 TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT AIBOTICS, INC. (Exact name of registrant as specified in its charter) Mycotopia Therapies Inc. (Previous name of registrant) Date: June 25, 2025 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Prim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 3 TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT AIBOTICS, INC. (Exact name of registrant as specified in its charter) Mycotopia Therapies Inc. (Previous name of registrant) Date: June 2, 2025 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Prima

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 2 TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT AIBOTICS, INC. (Exact name of registrant as specified in its charter) Mycotopia Therapies Inc. (Previous name of registrant) Date: May 29, 2025 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Prima

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 AIBiotics Therapies,

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): oForm 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: March 31, 2025 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Period

AMENDMENT TO ARTICLES OF INCORPORATION - INCREASE AUTHORIZED

CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in this Registration Statement to Form 1-A, Amendment No.

AMENDMENT TO ARTICLES OF INCORPORATION - NAME CHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A Amendment No. 1 TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT AIBOTICS, INC. (Exact name of registrant as specified in its charter) Mycotopia Therapies Inc. (Previous name of registrant) Date: May 6, 2025 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Primar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 AIBotics, Inc. (Exact nam

CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in this Registration Form 1-A (File No.

April 1, 2025

SEC FORM Exhibit 12.1 JONATHAN D. LEINWAND, P.A. 18305 Biscayne Blvd. Suite 200 Aventura, FL 33160 Tel: (954) 903-7856 Fax: (954) 252-4265 E-mail: [email protected] April 1, 2025 Board of Directors Aibotics, Inc. (formerly known as Mycotopia Therapies, Inc.) 100 SE 2nd St, Suite 2000 Miami, FL 33131 Ladies and Gentlemen: We are acting as counsel to Aibotics, Inc. (formerly know as Mycotopia Thera

CONSENT OF INDEPENDENT AUDITORS

CONSENT OF INDEPENDENT AUDITORS We hereby consent to the use in this Offering Circular on Form 1-A of our Report of Independent Registered Public Accounting Firm dated November 3, 2023, relating to the financial statements Aibotics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT AIBOTICS, INC. (Exact name of registrant as specified in its charter) Mycotopia Therapies Inc. (Previous name of registrant) Date: April 1, 2025 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Primary Standard Cla

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Pe

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2025 AIBOTICS, INC.

Software Development Agreement

Ben Kaplan,herein duly represented by it’s legal representative Ben Kaplan, herein after referred to as the “CONTRACTEE”.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mycotopia Therapies Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mycotopia Therapies Inc. (Exact name of registrant as specified in its charter) Nevada 87-0645794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 SE 2nd St, Suite 2000, Miami, FL 33131 (Address of Principal

Filing Fee Table

CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) MYCOTOPIA THERAPIES INC. (Exact name of Registrant as specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

Mycotopia Therapies Inc. 2024 Equity Incentive Plan

MYCOTOPIA THERAPIES INC. 2024 EQUITY INCENTIVE PLAN 1.Purpose of the Plan. This Plan is intended to promote the interests of the Company (as defined below) and its shareholders by providing employees, non-employee directors, consultants, and other selected service providers of the Company, who are largely responsible for the management, growth, and protection of the business of the Company, with i

Designation of Series A Super Voting Preferred Stock

CERTIFICATE OF DESIGNATION OF SERIES A SUPER VOTING PREFERRED STOCK OF MYCOTOPIA THERAPIES, INC.

Exchange Agreement with Ehave Inc.

EXCHANGE AGREEMENT This Exchange Agreement (the “Agreement”) is made this 29th day of July , 2024 by and between EHAVE INC.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 MYCOTOPIA THERAPIES, INC.

Amendment to Articles of Incorporation Increasing Authorized

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES

NT 10-Q 1 tpiant10q.htm MYCOTOPIA THERAPIES, INC. - NT10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 MYCOTOPIA THERAPIES, INC.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Pe

Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 MYCOTOPIA THERAPIES, INC.

Letter from Pinnacle Accountancy Group of Utah

Exhibit 16.1 March 27, 2024 Securities and Exchange Commission (the “Commission”) 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the former independent registered public accounting firm for Mycotopia Therapies, Inc. (the “Company”). We have read the statements made by the Company, which were provided to us and which we understand will be filed with the Commission pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934

Mycotopia Form Def-14c UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) ☒ Definitive Information Statement MYCOTOPIA THERAPIES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) ☐ Definitive Information Statement MYCOTOPIA THERAPIES INC.

Asset Purchase and Sale Agreement

ASSET SALE AND PURCHASE AGREEMENT This Asset Sale and Purchase Agreement (“Agreement”) is made as of November 28, 2023, by and between MYCOTOPIA THERAPIES, INC.

Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million

Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million Miami, FL – December 4, 2023 - Mycotopia Therapies Inc.

Intellectual Property Assignment Agreement

INTELLECTUAL PROPERTY ASSIGNMENT THIS ASSIGNMENT (this “Assignment”) is made as of November 14, 2023, between PHILON LABS, LLC.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 MYCOTOPIA THERAPIES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 MYCOT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 MYCOTOPIA THERAPIES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Period

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: March 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Perio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 MYCOTOPIA THERAPIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 MYCOTOPIA THERAPIES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 MYCOTOPIA THERAPIES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 MYCOTOPIA THERAPI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 MYCOTOPIA THERAPIES, INC.

Termination of Agreement and Plan of Merger

EX-10.1 2 tpiaex10z1.htm TERMINATION OF AGREEMENT AND PLAN OF MERGER TERMINATION OF AGREEMENT AND PLAN OF MERGER THIS TERMINATION OF AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of this day of February, 2023, by and among: PSLY.COM, INC., a Delaware corporation (“Parent”), - and - MYCOTOPIA THERAPIES INC., a Nevada corporation (“MTI”) - and - EI.VENTURES, INC., a Del

PSLY.com, Inc. Ei.Ventures, Inc. and Mycotopia Therapies Inc. Terminate Agreement and Plan of Merger

PSLY.com, Inc. Ei.Ventures, Inc. and Mycotopia Therapies Inc. Terminate Agreement and Plan of Merger Miami, FL and Maui, HI – February 21, 2023 - Ei.Ventures, Inc. (Ei.Ventures) and Mycotopia Therapies Inc. (“Mycotopia Therapies”)(OTC: TPIA) announced today that on February 16, 2023, PSLY.com, Inc., Ei.Ventures and Mycotopia Therapies agreed to mutually terminate the Agreement and Plan of Merger,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 MYCOTOPIA THERAPIES, INC.

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

EX-99.1 3 tpiaex99z1.htm PRESS RELEASE ANNOUNCING AGREEMENT AND PLAN OF MERGER Title: Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction Subhead: Entities on track to merge under PSLY.com and list on NASDAQ Stock Exchange May 19, 2022 from Miami, Florida and Maui, Hawaii: Ei.Ventures Inc. (“Ei”) today announced an update on the previously announc

Agreement and Plan of Merger with PSLY.com

AGREEMENT AND PLAN OF MERGER BY AND AMONG PSLY.COM, INC. (?PARENT?), MYCOTOPIA THERAPIES INC. (?MTI?), SILLY MERGER SUB M INC. (?MERGER SUB M?), SILLY MERGER SUB E INC. (?MERGER SUB E?), AND EI.VENTURES, INC. (?EVI?) DATED AS OF MAY , 2022 TABLE OF CONTENTS Article I. Definitions 6 Section 1.1. Definitions. 6 Section 1.2. Interpretation. 16 Article II. The Merger 16 Section 2.1. The Merger. 16 Sec

UNITED STATES

NT 10-Q 1 tpiant10q.htm MYCOTOPIA THERAPIES, INC. (FORM: NT 10-Q) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: March 31, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 MYCOTOPIA THERAPIES, INC.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Pe

UNITED STATES

NT 10-K 1 tpiant10k.htm MYCOTOPIA THERAPIES, INC..FORM: NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on

January 14, 2022

CORRESP 1 filename1.htm January 14, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services Attn: Ryan Lichtenfels Washington, D.C. 20549 Re: Mycotopia Therapies, Inc. Form 1-A Filed January 6, 2022 File No. 024-11770 Dear Mr. Lichtenfels: Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), Mycotopia

Kaplan Executive Consulting Agreement

EXECUTIVE CONSULTING AGREEMENT THIS EXECUTIVE CONSULTING AGREEMENT (the ?Agreement?), is entered into as of November 17, 2021 and effective as of the 19th day of January 2021, being the date upon which Consultant was appointed as CEO, is by and between on the one hand, Mycotopia Therapies, Inc.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 MYCOTOPIA THERAPIES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A

PART II AND III 2 tpia1a.htm PART II AND III UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A TIER 2 OFFERING OFFERING STATEMENT UNDER THE SECURITIES ACT OF 1933 CURRENT REPORT MYCOTOPIA THERAPIES, INC. (Exact name of registrant as specified in its charter) Date: January 6, 2022 Nevada 2833 87-0645794 (State or Other Jurisdiction of Incorporation) (Primary Standard

AUDITOR’S CONSENT Consent of Independent Registered Public Accounting Firm

EX1A-11 CONSENT 4 tpiaex11z1.htm CONSENT OF PINNACLE ACCOUNTANCY GROUP OF UTAH Exhibit 11.1 EXHIBIT AUDITOR’S CONSENT Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Offering Circular on Form 1-A of Mycotopia Therapies, Inc. of our report dated April 14, 2021, related to the consolidated financial statements of Mycotopia Therapies, Inc. as of December

December 20, 2021

SEC FORM Exhibit 12.1 JONATHAN D. LEINWAND, P.A. 18305 Biscayne Blvd. Suite 200 Aventura, FL 33160 Tel: (954) 903-7856 Fax: (954) 252-4265 E-mail: [email protected] December 20, 2021 Board of Directors Mycotopia Therapies, Inc. 18851 NE 29th Avenue, Suite 200 Aventura, FL 33180 Ladies and Gentlemen: We are acting as counsel to Mycotopia Therapies, Inc., a Nevada corporation (“TPIA”), for the purp

MYCOTOPIA THERAPIES, INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS

EX1A-4 SUBS AGMT 3 tpiaex4z1.htm SUBSCRIPTION AGREEMENT Exhibit 4.1 MYCOTOPIA THERAPIES, INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therap

UNITED STATES

NT 10-Q 1 tpiant10q.htm MYCOTOPIA THERAPIES, INC. (FORM: NT 10-Q) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: September 30, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report

Amendment to Articles of Incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

UNITED STATES

NT 10-Q 1 tpiant10q.htm MYCOTOPIA THERAPIES, INC. (FORM: NT 10-Q) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 Mycotopia Therapies,

Amendment to Bylaws

UNITED STATES

NT 10-Q 1 tpiant10q.htm MYCOTOPIA THERAPIES, INC. (FORM: NT 10-Q) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: March 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on F

Annual Report - 20/20 GLOBAL, INC. - FORM 10-K SEC FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 20/20 GLOBAL, INC. (Exact

- 20/20 GLOBAL, INC. - FORM NT 10K

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: February 28, 2022 Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Completion of Acquisition or Disposition of Assets

8-K/A 1 twgl8ka.htm 20/20 GLOBAL, INC.- FORM: 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 19, 2021 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-064579

- 20/20 GLOBAL SCH 14F-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14F OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER Commission File No. 000-56022 20/20 GLOBAL, INC. (Exact name of registrant as specified in its corporate charter) Nevada 87-0645794 (State of Incorporation) (IRS Employer Identification No.) 18851 NE 29

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 twgl8-k.htm 20/20 GLOBAL FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 20, 2021 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdic

Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector

Exhibit 99.01 Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector Company intends to focus on opportunities in the psychedelic space in the Caribbean and distribute Global 20/20 shares at a later date. MIAMI, Jan. 20, 2021 (GLOBE NEWSWIRE) - Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in di

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 19, 2021 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdiction of (Commission File Number) (IRS Em

MYCOTOPIA THERAPIES INC. FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 INDEX TO FINANCIAL STATEMENTS

EX-99.02 3 twglex99z02.htm FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPT. 30, 2020 Exhibit 99.02 MYCOTOPIA THERAPIES INC. FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 INDEX TO FINANCIAL STATEMENTS Page Balance Sheets as of September 30, 2020 and December 31, 2019 1 Statement of Operations for the Three and Nine Months Ended September 30, 2020 2 Statement of Changes in St

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA OF 20/20 GLOBAL, INC.

Exhibit 99.03 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA OF 20/20 GLOBAL, INC. The following unaudited pro forma combined condensed balance sheets and the unaudited pro forma combined condensed statements of operations is based on the separate historical balance sheet and statement of operations of 20/20 Global, Inc. and Mycotopia Therapies Inc. after giving effect to the acquisition. T

MYCOTOPIA THERAPIES INC. FINANCIAL STATEMENTS FOR THE PERIOD OF INCEPTION (DECEMBER 23, 2019) TO DECEMBER 31, 2019 INDEX TO FINANCIAL STATEMENTS

EX-99.01 2 twglex99z01.htm FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DEC. 31, 2019 Exhibit 99.01 MYCOTOPIA THERAPIES INC. FINANCIAL STATEMENTS FOR THE PERIOD OF INCEPTION (DECEMBER 23, 2019) TO DECEMBER 31, 2019 INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm 1 Balance Sheet as of December 31, 2019 2 Statement of Operations from inception (December 2

Amendment to Escrow Agreement and Definitive Agreements

AMENDMENT TO ESCROW AGREEMENT AND DEFINITIVE AGREEMENTS THIS AMENDMENT TO ESCROW AGREEMENT AND DEFINITIVE AGREEMENTS (this “Amendment”) is entered into effective this 4th day of January, 2021, by and among COLONIAL STOCK TRANSFER COMPANY, INC.

Current Report

8-K 1 twgl8k.htm 20/20 GLOBAL FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 4, 2021 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdicti

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 24, 2020 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdiction of (Commission File Number) (IRS E

Change of Control and Funding Agreement

Tew Separation and Release Agreement (June 2017) (00451315.DOCX;3) CHANGE OF CONTROL AND FUNDING AGREEMENT THIS CHANGE OF CONTROL AND FUNDING AGREEMENT (this “Change of Control Agreement”), effective as of the date of the last signature (the “Effective Date”), is made by and among 20/20 GLOBAL, INC., a Nevada corporation (“20/20 Global”), EHAVE INC., an Ontario corporation (“Ehave”), MYCOTOPIA THE

Stock Purchase Agreement between 20/20 Global, Inc. and Ehave, Inc.

Stock Purchase Agreement v2 - final (00211974.DOC;3) STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the “MYC SPA”) is made and becomes effective as of the date of last signature (the “Effective Date”), by and between 20/20 GLOBAL, INC., a Nevada corporation (“Purchaser”), and EHAVE INC., an Ontario corporation (“Seller”). Premises A.Purchaser is a publicly traded, fully reporting company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number 000-56022 20/20 GLOBAL, INC. (Exa

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.01 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of 20/20 Global, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), I, Mark D. Williams, Chief Executive Officer and Chief Financial

Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14

Exhibit 31.01 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14 I, Mark D. Williams, certify that: 1.I have reviewed this quarterly report on Form 10-Q of 20/20 Global, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

Quarterly Report - 20/20 GLOBAL, INC. - FORM 10-Q SEC FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number 000-56022 20/20 GLOBAL, INC. (Exact

-

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: February 28, 2022 Washington, D.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number 000-56022 20/20 GLOBAL, INC. (Exact

- 20/20 GLOBAL, INC. NT 10-Q

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: February 28, 2022 Washington, D.

TWGL / 20/20 Global, Inc. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56022 20/20 GLOBAL, INC. (Exact

Current Report

8-K BNA (18Aug2017) (00461903).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 6, 2020 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdiction of

Current Report

8-K BNA (18Aug2017) (00461903).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 27, 2019 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-56022 87-0645794 (State or other jurisdictio

TWGL / 20/20 Global, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number 000-56022 20/20 GLOBAL, INC. (Exa

Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14

Ex 31.01 Cert of PEO and PFO (10-K Dec 31 2016) (00437895.DOCX;1) Exhibit 31.01 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14 I, Mark D. Williams, certify that: 1.I have reviewed this quarterly report on Form 10-Q of 20/20 Global, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Ex 32.01 Cert of CEO (10-K 31Dec2016) (00437897.DOCX;1) Exhibit 32.01 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of 20/20 Global, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Mark D

Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14

Exhibit 31.01 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14 I, Mark D. Williams, certify that: 1.I have reviewed this quarterly report on Form 10-Q of 20/20 Global, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.01 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of 20/20 Global, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Mark D. Williams, Chief Executive Officer and Chief Financial Offic

TWGL / 20/20 Global, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number 000-56022 20/20 GLOBAL, INC. (Exact na

TWGL / 20/20 Global, Inc. NT 10-Q - - NT 10-Q

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: February 28, 2022 Washington, D.

TWGL / 20/20 Global, Inc. 10-12G/A - - 10-12G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 ) GENERAL FORM OF REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0645794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificati

TWGL / 20/20 Global, Inc. 10-12G/A - - 10-12G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1) GENERAL FORM OF REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0645794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificatio

TWGL / 20/20 Global, Inc. CORRESP - -

20/20 GLOBAL, INC. May 29, 2019 VIA EDGAR Scott Anderegg, Staff Attorney Division of Corporation Finance U.S. Securities and Exchange Commission Washington, D.C. 20549 Re:20/20 Global, Inc. Form 10-12G filed April 15, 2019 File No. 000-56022 Dear Mr. Anderegg: This letter is in response to your comments by letter of May 7, 2019. We have set forth your comments below, immediately followed by our re

Bylaws of 20/20 Global, Inc.

Amended and Restated Bylaws RMII - 20/20 (March 14 2014 - Final)) (00216284.DOC;2) BYLAWS OF 20/20 GLOBAL, INC. A NEVADA CORPORATION AS AMENDED AND RESTATED MARCH 14, 2014 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Principal Office 1 Section 1.02 Locations of Offices 1 ARTICLE II STOCKHOLDERS 1 Section 2.01 Annual Meeting 1 Section 2.02 Special Meetings 1 Section 2.03 Place of Meeting

Exchange Agreement and Plan of Reorganization by and among RM Investors, Inc., 20/20 Produce Sales, Inc., and Stockholders of 20/20 Produce Sales, Inc. dated March 14, 2014

Exchange Agreement and Plan of Reorganization (executed; schedules attached) (00220281.

TWGL / 20/20 Global, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM OF REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0645794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 480 22nd Stre

Specimen stock certificate

common stock certificate INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA NUMBER SHARES CUSIP NO: 90138D 10 7 20/20 GLOBAL, INC.

License Agreement with Markon Cooperative dated June 27, 2016

AGREEMENT FOR PURCHASE OF MARKON BRANDED AND BRAND APPROVED PRODUCT THIS AGREEMENT, effective June 27, 2016, is by and between 20/20 Produce Sales (hereinafter referred to as “Seller”), and MARKON COOPERATIVE, INC.

Supplier Authorization Agreement dated February 29, 2016

SUPPLIER AUTHORIZATION AGREEMENT-PRODUCE U.S. This Supplier Authorization Agreement - Produce (“Agreement”) is made as of the date set forth on the signature page (“Effective Date”) by and between 20/20 Produce Sales, Inc., a “C” Corporation, with a principal place of business at 480 22nd St., Heyburn, Idaho 83336 (“Supplier”), and Sysco Merchandising and Supply Chain, Inc., a Delaware corporation

Schedule of Subsidiaries

SUBSIDIARIES Name State of Organization 20/20 Produce Sales, Inc. Idaho

Produce Fixed-Term Purchase Agreement dated February 29, 2016

PRODUCE FIXED TERM PURCHASE AGREEMENT This Produce Fixed Term Purchase Agreement (this “Agreement”), is between Sysco Merchandising and Supply Chain Services, Inc.

Amended and Restated Articles of Incorporation of 20/20 Global, Inc.

Amended & Restated Articles RMII - 20/20 Global (March 14 2014 - Final) (00216090.

TWGL / 20/20 Global, Inc. RW

20/20 GLOBAL, INC. March 15, 2019 VIA EDGAR Scott Anderegg, Staff Attorney Division of Corporation Finance U.S. Securities and Exchange Commission Washington, D.C. 20549 Re:20/20 Global, Inc. Form 10-12G filed January 31, 2019 File No. 000-56022 Dear Mr. Anderegg: 20/20 Global, Inc. hereby applies for the consent of the U.S. Securities and Exchange Commission to withdraw the Registration Statement

TWGL / 20/20 Global, Inc. FORM 10

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM OF REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 20/20 GLOBAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0645794 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 480 22nd Stre

Amended and Restated Articles of Incorporation of 20/20 Global, Inc.

Amended & Restated Articles RMII - 20/20 Global (March 14 2014 - Final) (00216090.

License Agreement with Markon Cooperative dated June 27, 2016

AGREEMENT FOR PURCHASE OF MARKON BRANDED AND BRAND APPROVED PRODUCT THIS AGREEMENT, effective June 27, 2016, is by and between 20/20 Produce Sales (hereinafter referred to as “Seller”), and MARKON COOPERATIVE, INC.

Exchange Agreement and Plan of Reorganization by and among RM Investors, Inc., 20/20 Produce Sales, Inc., and Stockholders of 20/20 Produce Sales, Inc. dated March 14, 2014

Exchange Agreement and Plan of Reorganization (executed; schedules attached) (00220281.

Specimen stock certificate

common stock certificate INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA NUMBER SHARES CUSIP NO: 90138D 10 7 20/20 GLOBAL, INC.

Produce Fixed-Term Purchase Agreement dated February 29, 2016

PRODUCE FIXED TERM PURCHASE AGREEMENT This Produce Fixed Term Purchase Agreement (this “Agreement”), is between Sysco Merchandising and Supply Chain Services, Inc.

Bylaws of 20/20 Global, Inc.

Amended and Restated Bylaws RMII - 20/20 (March 14 2014 - Final)) (00216284.DOC;2) BYLAWS OF 20/20 GLOBAL, INC. A NEVADA CORPORATION AS AMENDED AND RESTATED MARCH 14, 2014 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Principal Office 1 Section 1.02 Locations of Offices 1 ARTICLE II STOCKHOLDERS 1 Section 2.01 Annual Meeting 1 Section 2.02 Special Meetings 1 Section 2.03 Place of Meeting

Supplier Authorization Agreement dated February 29, 2016

SUPPLIER AUTHORIZATION AGREEMENT-PRODUCE U.S. This Supplier Authorization Agreement - Produce (“Agreement”) is made as of the date set forth on the signature page (“Effective Date”) by and between 20/20 Produce Sales, Inc., a “C” Corporation, with a principal place of business at 480 22nd St., Heyburn, Idaho 83336 (“Supplier”), and Sysco Merchandising and Supply Chain, Inc., a Delaware corporation

Schedule of Subsidiaries

SUBSIDIARIES Name State of Organization 20/20 Produce Sales, Inc. Idaho